Acuta Capital Partners, LLC Aadi Bioscience, Inc. Transaction History
Acuta Capital Partners, LLC
- $122 Million
- Q1 2024
A detailed history of Acuta Capital Partners, LLC transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 1,849,402 shares of AADI stock, worth $3.14 Million. This represents 3.54% of its overall portfolio holdings.
Number of Shares
1,849,402
Previous 1,849,402
-0.0%
Holding current value
$3.14 Million
Previous $3.74 Million
15.85%
% of portfolio
3.54%
Previous 2.91%
Shares
2 transactions
Others Institutions Holding AADI
# of Institutions
64Shares Held
13.7MCall Options Held
4.9KPut Options Held
700-
Avoro Capital Advisors LLC New York, NY2.85MShares$4.84 Million0.08% of portfolio
-
Satter Management Co., L.P.1.63MShares$2.77 Million4.26% of portfolio
-
Black Rock Inc. New York, NY1.04MShares$1.77 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA857KShares$1.46 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny544KShares$924,3270.0% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $35.7M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...